In the anthracycline only group, 1.4 percent of patients subsequently developed cardiomyopathy/heart failure with no incident heart failure noted in the VEGF inhibitor or combined therapy groups during follow-up. The gene discussed is VEGFA; the disease is cardiomyopathy.